Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.45 |
| ▸ | DPP4 | P27487 | 4/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19097252 | 1.00 | KCNK3 (0.46) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17328111 | 1.00 | KCNK3 (0.46) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17328080 | 0.92 | ENPP2 (0.47) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17328165 | 0.92 | ENPP2 (0.47) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL19097241 | 0.92 | ENPP2 (0.47) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17328192 | 0.91 | KCNK3 (0.45) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17328136 | 0.91 | KCNK3 (0.45) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17317490 | 0.91 | KCNK3 (0.45) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17328158 | 0.90 | ENPP2 (0.50) | KCNK3ENPP2DPP4DPP7DPP8 | |
| SCHEMBL17317759 | 0.90 | ENPP2 (0.50) | KCNK3ENPP2DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | claimed |
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885ENPP2 1/4885DPP4 2232/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885ENPP2 1/4885DPP4 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.